AI Article Synopsis
- Biological therapy has significantly improved disease control and quality of life for patients with autoimmune diseases, but it also raises the risk of certain infections due to changes in immune response.
- Current risk assessment methods for these therapies are not well-developed for populations in tropical regions and developing countries, where infectious diseases are more common.
- The study reviewed the impact of infections related to biological therapy and explored strategies to reduce risks in areas heavily affected by tropical diseases.
Article Abstract
In recent decades, biological therapy has enabled disease activity control and improved quality of life in patients with autoimmune diseases. These therapies that are involved in immune response modifications and change multiple immunological pathways induce an incremental risk for certain infectious diseases. Though there have been recent advances in risk assessment for biological therapy, there is a lack of data and recommendations for assessing risks in populations with high prevalence of infectious diseases, such as those located in tropical areas and developing countries. We performed a review on infections with biological therapy as well strategies for risk minimization in areas with a high prevalence of tropical diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3855/jidc.8222 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!